Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT03673137

Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC

Phase II/III of Randomized Controlled Clinical Research on Irreversible Electroporation Synchronous Chemotherapy for Locally Advanced Pancreatic Adenocarcinoma

Sponsor: Fuda Cancer Hospital, Guangzhou

Conditions Locally Advanced Pancreatic Adenocarcinoma

Interventions Gemcitabine Irreversible electroporation

Updated 7 times since 2018 Last updated: Sep 1, 2021 Started: Sep 1, 2019 Primary completion: Jun 30, 2021 Completion: Jul 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Locally Advanced Pancreatic Adenocarcinoma and is currently completed. Fuda Cancer Hospital, Guangzhou leads this study, which shows 7 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Oct 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3

Status: Recruiting → Completed
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE2_PHASE3
Jun 2020 — Jan 2021 [monthly]

Recruiting PHASE2_PHASE3

▶ Show 2 earlier versions

Oct 2019 — Jun 2020 [monthly]

Recruiting PHASE2_PHASE3

Status: Not Yet Recruiting → Recruiting
Oct 2018 — Oct 2019 [monthly]

Not Yet Recruiting PHASE2_PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fuda Cancer Hospital, Guangzhou

Data source: Fuda Cancer Hospital, Guangzhou

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China